Chordoma of the Sacrum

Clinical Guide: Chordoma of the Sacrum

1. Comprehensive Introduction & Overview

Chordoma of the sacrum is a rare, slow-growing, locally aggressive malignant neoplasm derived from embryonic remnants of the notochord. While chordomas can occur anywhere along the axial skeleton—from the clivus to the coccyx—the sacrococcygeal region is the most frequent site of origin, accounting for approximately 50% of all cases.

Clinically, sacral chordomas are characterized by their indolent growth pattern, often leading to a significant delay in diagnosis. By the time of clinical presentation, these tumors are frequently large, involving the sacral canal, pelvic viscera, and surrounding soft tissues. Because of their anatomical location and their propensity for local recurrence, they represent a significant challenge for orthopedic oncologists and neurosurgeons alike.

2. Deep-Dive: Etiology and Pathophysiology

The Notochordal Origin

The notochord is a primitive structure that serves as the axial skeleton of the developing embryo. In normal development, the notochord regresses; however, vestigial cells may persist within the intervertebral discs and the vertebral bodies. These ectopic or residual cells are the hypothesized progenitors of chordomas.

Molecular and Genetic Mechanisms

• Brachyury (T-box transcription factor): The hallmark of chordoma is the expression of the brachyury protein. Brachyury is essential for notochordal development, and its constitutive expression is a highly sensitive and specific diagnostic marker for chordoma.
• TBXT Gene: Genetic studies have identified duplications or germline mutations in the TBXT gene (which encodes brachyury) in familial chordoma cases.
• Loss of Heterozygosity (LOH): Frequent loss of chromosome 1p and 9p is observed, often involving the CDKN2A locus, which regulates cell cycle progression.

Histological Subtypes

Understanding the histology is critical for determining prognosis and treatment aggressiveness.

3. Clinical Presentation and Indications

Standard Clinical Presentation

Due to the slow growth, symptoms are often vague and progress over months or years. Patients typically present in the 5th or 6th decade of life.

1. Pain: Persistent, dull, aching pain in the lower back or sacral region.
2. Neurological Deficits: Radiculopathy, sacral nerve root compression (S2-S4), leading to saddle anesthesia or paresthesia.
3. Bowel/Bladder Dysfunction: Late-stage manifestation due to compression of the autonomic sacral plexus.
4. Palpable Mass: A rectal examination may reveal a firm, retrorectal mass.

Diagnostic Workup and Staging

Staging is generally performed using the Enneking system for musculoskeletal tumors, which focuses on the compartmentalization of the tumor.

Essential Imaging Modalities

• MRI (Gold Standard): Essential for evaluating soft tissue extension, nerve root involvement, and the relationship to the pelvic floor. Chordomas are typically hyperintense on T2-weighted sequences.
• CT Scan: Superior for assessing the extent of bone destruction and cortical breakthrough.
• PET/CT: Used primarily for systemic staging to rule out distant metastases (lungs, liver, bone).

Biopsy Considerations

CRITICAL WARNING: Biopsy of a suspected sacral chordoma should only be performed by the orthopedic oncology team that will perform the definitive surgery. Improper biopsy tract placement can lead to tumor seeding and necessitate a much more radical, morbid resection.

4. Differential Diagnosis

Distinguishing sacral chordoma from other pathologies is essential for appropriate management.

• Chondrosarcoma: Often presents with "rings and arcs" calcification on CT; does not express Brachyury.
• Giant Cell Tumor (GCT) of Bone: Typically involves the sacral body rather than the midline; shows osteoclast-like giant cells on histology.
• Sacral Schwannoma: Usually cystic components; lacks the destructive osseous pattern of chordoma.
• Metastatic Carcinoma: Prostate, breast, or lung cancer metastasis. Often presents as a multifocal disease.
• Lymphoma: Often presents with systemic symptoms (B-symptoms) and responds to chemotherapy/radiation.

5. Treatment Paradigms

Surgical Management

The primary treatment goal is wide en-bloc resection. Because chordomas are notoriously resistant to chemotherapy and conventional radiation, the surgical margin is the most significant prognostic factor.

• Total Sacrectomy: Required for high-level tumors.
• Subtotal/Intralesional Resection: Generally avoided due to the extremely high rate of local recurrence (approaching 100% without adjuvant therapy).

Adjuvant Therapy

• Proton Beam Therapy (PBT): Given the proximity to the rectum and bowel, high-dose radiation is required to control microscopic disease, but toxicity is a concern. PBT allows for "Bragg peak" delivery, sparing anterior structures.
• Systemic Therapy: Generally reserved for unresectable or metastatic disease. Tyrosine kinase inhibitors (TKIs) like Imatinib or Sorafenib have shown modest efficacy in targeting the PDGFR pathway.

6. Risks, Complications, and Contraindications

Surgical Risks

• Neurological Deficits: Sacrifice of sacral nerve roots is often necessary for tumor clearance, leading to permanent bowel/bladder incontinence and sexual dysfunction.
• Wound Complications: The sacral region is prone to poor healing, especially post-radiation. Dehiscence and deep space infection are significant risks.
• Structural Instability: Resection of the sacrum requires complex spinopelvic reconstruction (e.g., Galveston rods or iliosacral screws).

Contraindications

• Surgical: Severe medical comorbidities precluding major reconstructive surgery.
• Radiological: Massive anterior visceral involvement that cannot be cleared without total pelvic exenteration, which may be deemed palliative rather than curative in certain contexts.

7. Frequently Asked Questions (FAQ)

1. Is sacral chordoma cancer?
Yes, it is a malignant bone tumor. While slow-growing, it is considered locally aggressive and has the potential to metastasize.

2. What is the most common symptom of a sacral chordoma?
Persistent lower back pain or sacral pain that does not resolve with conservative management.

3. Why is the biopsy so restricted?
Because the tumor is "seeding-prone." If the biopsy needle tracks through healthy tissue, the tumor cells can spread along that track, making future surgery impossible to clear.

4. Can chordoma be cured with radiation alone?
No. Surgery is the cornerstone of treatment. Radiation is used as an adjuvant to control microscopic residual disease.

5. What is the role of Brachyury?
It is a diagnostic marker. If a tumor does not express Brachyury, it is statistically unlikely to be a chordoma.

6. Will I lose my ability to walk after surgery?
If the surgery is below S2, ambulatory function is usually preserved. If higher sacral nerves are involved, significant weakness may occur, requiring orthotics or rehabilitation.

7. How often does sacral chordoma recur?
Even with successful surgery, the recurrence rate is high. Close surveillance with MRI for 10+ years is required.

8. Is chemotherapy effective?
Standard cytotoxic chemotherapy is generally ineffective. Targeted therapies (TKIs) are the current standard for palliative management.

9. What is the prognosis?
The 5-year survival rate is approximately 60-70%, but this is heavily dependent on the ability to achieve clean surgical margins.

10. Why is proton radiation preferred over X-ray radiation?
Proton therapy allows for a more precise dose distribution, minimizing "exit dose" to the pelvic organs and reducing the risk of radiation-induced bowel complications.

8. Long-Term Prognosis and Surveillance

The prognosis for patients with sacral chordoma is guarded but potentially favorable if diagnosed early and treated with high-volume center expertise.

Surveillance Schedule

• Years 1–2: MRI/CT every 3–6 months.
• Years 3–5: MRI/CT every 6 months.
• Years 5–10: Annual MRI/CT.

Patients must be monitored not only for local recurrence but also for distant metastasis, which typically occurs in the lungs, followed by the liver and lymph nodes.

Quality of Life (QoL)

Post-operative QoL is significantly impacted by the loss of sacral nerve function. Multidisciplinary care, including physical therapy, pain management, and urological/gastroenterological support, is essential for patients undergoing sacral resection.

Disclaimer: This guide is intended for informational and educational purposes for medical professionals. It does not replace the judgment of a board-certified orthopedic oncologist. Always consult institutional protocols and current NCCN guidelines regarding the management of primary bone sarcomas.

Related Clinical Integration

The management of a sacral chordoma necessitates a multidisciplinary surgical approach, as the primary objective is achieving wide oncological margins to minimize the high risk of local recurrence. Depending on the tumor's size, anatomical extent, and involvement of adjacent neurovascular structures, the clinical team may perform a Partial or Total Sacrectomy / استئصال جزئي أو كلي للعجز (عملية كبرى في غرف العمليات) to ensure complete resection. In cases where the malignancy is localized or requires less extensive structural removal, a standard Bone Tumor Excision / استئصال ورم العظم (عملية كبرى في غرف العمليات) may be indicated, whereas more aggressive, complex presentations often require a Radical Resection of Bone Tumor (Limb Salvage) / استئصال جذري لورم عظمي (لإنقاذ الطرف) (عملية كبرى في غرف العمليات) to preserve functional mobility while ensuring the total eradication of the neoplastic tissue.